CompletedPhase 2

Study of FYU-981 in Hyperuricemia With or Without Gout

Japan200 participantsStarted 2015-05

Plain-language summary

The purpose of this study is confirmatory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered orally to hyperuricemic patients with and without gout for 12 weeks (dose-escalating initial period: 4 weeks followed by maintenance period: 8 weeks) by the method of randomized (dynamic allocation), placebo-controlled, double-blind, parallel group comparison.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Hyperuricemic or gout patients * Serum urate level: \>= 7.0mg/dL in patients with history of gout, or \>= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or \>= 9.0mg/dL Exclusion Criteria: * Gouty arthritis within two weeks before start of study treatment * Secondary hyperuricemia * HbA1c: \>= 8.4% * Uric acid-overproduction type in the classification of hyperuricemia * History of, clinically significant cardiac, hematologic and hepatic disease * Kidney calculi or clinically significant urinary calculi * eGFR: \< 30mL/min/1.73m\^2 * Systolic blood pressure: \>= 180 mmHg * Diastolic blood pressure: \>= 110 mmHg

What they're measuring

Percent reduction from baseline in serum urate level at the final visit

Timeframe: 12 weeks

Trial details

NCT IDNCT02416167

SponsorFuji Yakuhin Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2016-05

View on ClinicalTrials.gov More Hyperuricemia trials